Grand Pharmaceutical Group Limited
遠大醫藥集團有限公司*
(Incorporated in Bermuda with limited liability)
(Stock Code: 00512)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2021 AND 2022 ANNUAL REPORTS

Reference is made to the 2021 annual report and 2022 annual report of Grand Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") published on 25 April 2022 and 27 April 2023 respectively (the "**Annual Reports**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Annual Reports.

The Board would like to provide supplemental information regarding the disclosure of Directors' and employees' emoluments in the Annual Reports. In June 2021, Mr. Zhou Chao ("**Mr. Zhou**") was promoted to the chief executive officer of the Company and in accordance with paragraphs 24 and 24.5 of Appendix D2 to the Listing Rules, his emoluments shall be disclosed as a director. Therefore, the contents of note 15 to the consolidated financial statements set out in the Annual Reports shall be updated as follows:

(a) Directors' emoluments

	2022 HK$'000	**2021** HK$'000
Fees:		
Executive directors	58	92
Independent non-executive directors	395	340
	453	432
Other emoluments:		
Salaries and allowances	7,039	7,567
Retirement benefits scheme contributions	138	61
	7,630	8,060

No emoluments were paid by the Group to the directors as an inducement to join, or upon joining the Group, or as compensation for loss of office for both years ended 31 December 2022 and 2021.

The emoluments paid or payable to each of the seven (2021: nine) directors and the chief executive officer for the year ended 31 December 2022 are as follows:

	Fees HK$'000	Salaries and allowances HK$'000	Retirement benefits schemes contributions HK$'000	Total HK$'000
Executive directors:				
Dr. Tang Weikun (Chairman)	-	2,812	102	2,914
Dr. Shao Yan	-	1,958	18	1,976
Dr. Niu Zhanqi	58	-	-	58
Dr. Shi Lin	-	1,014	-	1,014
Independent non-executive directors:				
Ms. So Tosi Wan, Winnie	209	-	-	209
Mr. Hu Yebi	116	-	-	116
Dr. Pei Geng	70	-	-	70
Chief Executive Officer:				
Mr. Zhou Chao	-	1,255	18	1,273
Total	453	7,039	138	7,630

Details of the emoluments of the directors (including the chief executive officer) for the year ended 31 December 2021 are as follows:

	Fees HK$'000	Salaries and allowances HK$'000	Retirement benefits schemes contributions HK$'000	Total HK$'000
Executive directors:				
Mr. Liu Chengwei (retired on 1 June 2021)	21	-	-	21
Mr. Hu Bo (retired on 1 June 2021)	21	-	-	21
Dr. Shao Yan	-	2,345	18	2,363
Dr. Niu Zhanqi	50	-	-	50
Dr. Tang Weikun (Chairman) (appointed on 1 June 2021)	-	1,073	25	1,098
Dr. Shi Lin (appointed on 1 June 2021)	-	661	-	661
Independent non-executive directors:				
Ms. So Tosi Wan, Winnie	180	-	-	180
Mr. Hu Yebi	100	-	-	100
Dr. Pei Geng	60	-	-	60
Chief Executive Officer:				
Mr. Zhou Chao	-	3,488	18	3,506
Total	453	7,567	61	8,060

During year ended 31 December 2022 and 2021, no director of the Company agreed to waive or waived any emoluments.

(b) Five Highest Paid Individuals

The five individuals with the highest emoluments in the Group, none (2021: two) were the director or chief executive officer of the Company whose emoluments were included above. The emoluments of the remaining five (2021: three) individuals are as follows:

	2022 **HK$'000**	**2021** **HK$'000**
Employees		
Salaries and allowances	22,347	7,954
Retirement benefits schemes contributions	980	425
	23,327	8,379

These emoluments were within the following bands:

	2022 **No. of employees**	**2021** **No. of employee**
Nil to HK$3,000,000	-	3
HK$3,000,001 to HK$3,500,000	2	-
HK$3,500,001 to HK$4,000,000	1	-
Over HK$4,000,000	2	-
	5	3

During both years ended 31 December 2022 and 2021, no emoluments were paid by the Group to the five highest paid individuals as an inducement to join or upon joining the Group or as compensation for loss of office.

(c) Senior Management of the Group

The emoluments of the senior management who are not director and chief executive officer of the Group are within the following band:

	2022 **No. of employees**	**2021** **No. of employee**
Nil to HK$1,000,000	-	1
HK$1,000,001 to HK$1,500,000	1	2
HK$1,500,001 to HK$2,000,000	-	-
Over HK$2,000,000	1	1
	2	4

During years ended 31 December 2022 and 2021, no emoluments were paid by the Group to the senior management as an inducement to join or upon joining the Group or as compensation for loss of office.

Save as aforesaid, all other contents of the Annual Reports remain unchanged.

By order of the Board
Grand Pharmaceutical Group Limited
Chairman
Dr. Tang Weikun

Hong Kong, 4 December 2025

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica, and four independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*